• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: Recombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminus
Date Designated: 07/20/2022
Orphan Designation: Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Kira Pharmaceuticals, LLC
245 Main Street
Cambridge, Massachusetts 02142
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-